Clinical trial · Observational
Study of Management and Prognosis of Patients With Acute Myeloblastic Leukemia in Saint-Antoine Hospital
NCT05558943CI-TRIAL-00088014LAMSAnot yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
AML in adults represents a group of heterogeneous diseases; the prognosis remains poor despite significant therapeutic advances in recent years. In order to optimize patient care, it is necessary to have "real life" data that exhaustively reports on the patients treated in our department. The objective of this study is: * To describe the AML treated within the hematology department * To optimize the management of patients with AML.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- 2 years after diagnosis
Secondary outcomes (7)
- measure
- Overall survival
- timeFrame
- 6 months after diagnosis
- measure
- Overall survival
- timeFrame
- 1 year after diagnosis
- measure
- Cytological remission rate
- timeFrame
- after the phase of induction up to 24 months
- measure
- Incomplete cytological remission rate
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age :18 years and older * Patients with AML * Non objection to research Exclusion Criteria: * Minor patients * Acute promyelocytic leukemia (AML3)
References
Publications (0)
Data not yet available
No reference posted for this study.